MyMD Pharmaceuticals, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
6MyMD Pharmaceuticals's Business Model
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
About MyMD Pharmaceuticals
Website: https://www.mymd.com
CEO (Chief Executive Officer): Dr. Christopher C. Chapman Jr., M.D.
IPO date: 2014-01-23
Contact
Country: US
Address: 855 North Wolfe Street
City: Baltimore
State: MD
Phone: 856 848 8698
Zip Code: 21205
Other
CIK: 0001321834
ISIN: US62856X2018
CUSIP: 00973E409
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
